In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Qiagen buys artus for cash and earn-outs

Executive Summary

Qiagen NV (products and services for nucleic acid and protein separation, purification, and handling) is acquiring artus GMBH, a developer of PCR-based molecular diagnostics used in pathogen detection, genotyping, and pharmacogenomics. The company will pay about €17mm ($21.3mm) in cash, plus an additional $11.6mm in potential earn-outs.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Includes Earnout
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register